Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma plc (~292)

  Print      Mail a friend       Annual reports

Tuesday 05 September, 2006

Antisoma plc

Second dramatic response seen with Antisoma's A...

London, UK and Louisville, Kentucky, 5 September 2006 - Antisoma
today announces that a second late-stage renal cancer patient in its
phase I trial of AS1411 has experienced major tumour shrinkage. This
follows a similar case reported earlier from the same trial.

The latest responder had four separate tumours at different sites,
with an aggregate total diameter before treatment of almost 20cm. Six
months after starting treatment with AS1411 overall tumour shrinkage
was around 70%, clearly qualifying as a partial response. This
outcome is particularly notable because the patient had relapsed
after three prior therapies: interleukin-2, gemcitabine and
interferon plus Avastin.

Dr Damian Laber, Principal Investigator in the trial commented: "It
is exciting to see a second case of profound tumour shrinkage in this
relatively small study. We are particularly encouraged to see a
response like this in a patient who has already failed several
previous therapies."

Full data from the AS1411 trial will be presented at the European
Society of Medical Oncology (ESMO) meeting on October 1st by
Professor Donald Miller, Director of the Brown Cancer Center in
Louisville, Kentucky, where the trial was conducted. Following its
extension last year, the trial includes twelve patients with renal
cancer and five with lung cancer.

Glyn Edwards, Antisoma's CEO, said: "We are delighted to see further
clinical evidence for AS1411 activity against renal cancer. We are
also seeing activity across a wide range of other solid and blood
cancers in preclinical studies. These findings, together with the
very benign safety profile seen so far, make us very excited about
the potential of AS1411."

Glyn Edwards, CEO
Daniel Elger, Director of
Communications                                 +44 (0)20 8799 8200
Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich                   +44
(0)20 7466 5000
Buchanan Communications

Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes for Editors:
The response of tumours to treatment is commonly measured using
RECIST (Response Evaluation Criteria in Solid Tumours) to evaluate
tumours imaged on CT or other scans. Possible outcomes include
complete response (disappearance of all tumours), partial response
(more than 30% but less than 100% reduction in the sum of the longest
diameters of 'target' tumour lesions), stable disease (between a 30%
reduction and a 20% increase in the sum of lesion measurements) and
progressive disease (greater than 20% increase in the sum of lesion
sizes or appearance of new lesions). The patient described in this
release therefore had a clear partial response.

Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. Please visit for further information about Antisoma.



a d v e r t i s e m e n t